reports
CSX Executive Vice President and Chief Commercial Officer to Address B...
CSX Executive Vice President and Chief Commercial Officer to Address Bank of America Transportation, Airlines and Industrials Conference JACKSONVILLE, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Commercial Officer, Kevin Boone, will address the Bank of America Transportation, Airlines and Industrials Conference in New York on Tuesday, May 14, at 8:00 a.m. Eastern time. This address will be broadcast live via webcast at . A replay will be available following the conclusion of this event. This announcement, as well as additional financ...
Corvus Pharmaceuticals to Provide Business Update and First Quarter 20...
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domesti...
BJ’s Restaurants, Inc. Reports Fiscal First Quarter 2024 Results
BJ’s Restaurants, Inc. Reports Fiscal First Quarter 2024 Results HUNTINGTON BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BJ’s Restaurants, Inc. (NASDAQ: BJRI) today reported financial results for its fiscal 2024 first quarter ended Tuesday, April 2, 2024. Fiscal First Quarter 2024 Compared to First Quarter 2023 Total revenues decreased 1.2% to $337.3 millionComparable restaurant sales declined 1.7%Total restaurant operating weeks increased by one weekNet income of $7.7 million, compared to $3.5 million; diluted net income per share of $0.32, compared to $0.15Adjusted EBIT...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares o...
Mustang Bio Announces Closing of $4 Million Public Offering
Mustang Bio Announces Closing of $4 Million Public Offering Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 16,877,638 shares of its common stock ...
WW International, Inc. Announces First Quarter 2024 Results
WW International, Inc. Announces First Quarter 2024 Results End of Period Subscribers of 4.0 million, including 91 thousand End of Period Clinical SubscribersRevenues of $206.5 millionGross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross margin of 67.9%Operating Loss of $269.3 million primarily due to $258.0 million in non-cash intangible impairment charges for franchise rights acquired; excluding such impairment charges and the net impact of restructuring charges related to prior year restructuring plans, adjusted...
Upland Software Reports First Quarter 2024 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)-- Upland Software, Inc. (Nasdaq: UPLD), a leader in cloud-based tools for digital transformation, today announced financial and operating results for the first quarter 2024 and issued guidance for its second quarter and full year of 2024. First Quarter 2024 Financial Highlights Total revenue was $70.7 million, a decrease of 8% from $77.1 million in the first quarter of 2023. Subscription and support revenue was $67.1 million, a decrease of 8% from $72.9 million in the first quarter of 2023. GAAP net loss was $96.1 million compared to a GAAP net loss of...
Galapagos reports first quarter 2024 financial results
Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance o...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024 Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten afgesloten met BridGene Biosciences en Thermo Fisher Scientific, en investering in Frontier MedicinesJyseleca® business overgedragen aan Alfasigma S.p.A., waardoor middelen vrijkomen om te investeren in groeigebiedenNetto groepsomzet in het eerste kwartaal van €100 miljoenGeldmiddelen en kortlopende financiële investeringen van €...
Gevo Reports First Quarter 2024 Financial Results
Gevo Reports First Quarter 2024 Financial Results Gevo to Host Conference Call Today at 4:30 p.m. ET ENGLEWOOD, Colo., May 02, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter 2024 and recent corporate highlights. Recent Corporate Highlights Share repurchases: Gevo began utilizing its previously announced stock repurchase program. Through May 2, 2024, we repurchased approximately 5.5 million shares of our common stock for approximately $3.7 million, which leaves approximately $21.3 m...
Alignment Healthcare Reports First Quarter 2024 Results
Alignment Healthcare Reports First Quarter 2024 Results Reports $628.6 million in total revenue and $627.6 million in revenue excluding ACO REACH, up 43.1% and 54.2% year-over-year respectivelyMedicare Advantage membership grows 50.5% year-over-year to approximately 165,100 membersIncreases membership and revenue outlook following strong first-quarter enrollment results, narrows year-end adjusted EBITDA guidance range ORANGE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial results for its first quarter ended March 31, 2024. “A...
Willscot Mobile Mini Reports First Quarter 2024 Results
Willscot Mobile Mini Reports First Quarter 2024 Results Solid Modular and Value-Added Products Demand Support Full Year 2024 Outlook PHOENIX, May 02, 2024 (GLOBE NEWSWIRE) -- WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced first quarter 2024 results and provided an update on operations and the current market environment, including the following highlights: Q1 2024 Revenue increased 4% to $587 million and Income from continuing operations was $56 million. Income from ...
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Ex...
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in...
Asure Announces First Quarter 2024 Results
Asure Announces First Quarter 2024 Results Reports First Quarter Revenues of $31.7 Million Management Reiterates 2024 Revenue Guidance of $125.0 Million - $129.0 Million AUSTIN, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Asure Software, Inc. (“we”, “us”, “our”, “Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $31.7 million, down 4% year over yearRevenue (excluding ERTC revenue) of $30.7 millio...
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D....
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D., the Company’s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information: Date:Thursday, May 9, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Dial-In: (800) 715-9871 ...
EMCORE Announces Sale of Chips Business and Wafer Fabrication Operatio...
EMCORE Announces Sale of Chips Business and Wafer Fabrication Operations for $2.92M and Certain Assumed Liabilities BUDD LAKE, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, announced today the consummation effective April 30, 2024 of a transaction for the sale of its Chips business and indium phosphide (InP) wafer fabrication operations for a total purchase price of $2.92 million, together with the assumption by the buyer, HieFo Corporation, of certain...
Silvercrest Asset Management Group Inc. Reports Q1 2024 Results
Silvercrest Asset Management Group Inc. Reports Q1 2024 Results NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter ended March 31, 2024. Business Update Supportive equity markets in the first quarter of 2024 set the stage for a better environment for our business, continuing progress that began in the fourth quarter of 2023 as the market broadened. While we continue to expect an uncertain economic and market environment, Silvercrest has never had ...
Ascendis Pharma Reports First Quarter 2024 Financial Results
Ascendis Pharma Reports First Quarter 2024 Financial Results — Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch planned in Q3 — TransCon CNP (navepegritide) pivotal ApproaCH Trial on track for topline results in Q4 2024 — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses fell by 20% year-over-year to €13...
Badger Announces Voting Results of 2024 Annual Meeting of Shareholders
Badger Announces Voting Results of 2024 Annual Meeting of Shareholders CALGARY, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) is pleased to announce that all of the motions put forward at its annual meeting of shareholders held on May 2, 2024 (the “Meeting”) were approved by its shareholders. A total of 27,975,548 common shares in the capital of the Company, representing approximately 81.15% of the issued and outstanding common shares, were represented in person or by proxy at the Meeting. All nine direc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.